SCYNEXIS, Inc. Deferred Tax Assets, Operating Loss Carryforwards
SCYNEXIS, Inc. (SCYX) had Deferred Tax Assets, Operating Loss Carryforwards of $51.38 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $51.38M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $48.68M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $46.44M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $88.36M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $51.38M 10-K · filed 2026-03-04 |
| 2024-12-31 | $48.68M 10-K · filed 2026-03-04 |
| 2023-12-31 | $46.44M 10-K · filed 2025-03-12 |
| 2022-12-31 | $88.36M 10-K · filed 2024-03-28 |
| 2021-12-31 | $80.45M 10-K · filed 2023-03-31 |
| 2020-12-31 | $70.94M 10-K · filed 2022-03-29 |
| 2019-12-31 | $58.07M 10-K · filed 2021-03-29 |
| 2018-12-31 | $44.73M 10-K · filed 2020-03-11 |
| 2017-12-31 | $40.50M 10-K · filed 2019-03-14 |
| 2016-12-31 | $53.17M 10-K · filed 2018-03-13 |
| 2015-12-31 | $42.36M 10-K · filed 2017-03-13 |
| 2014-12-31 | $29.98M 10-K · filed 2016-03-07 |
| 2013-12-31 | $26.29M 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |